Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

atment and prevention of recurrence of venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation, respectively.1,2,8

Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name Lixiana®. Elsewhere, including Europe and the US, edoxaban is currently in phase 3 clinical development and has not been approved in any indication.9 Results from the Hokusai-VTE clinical trial were presented at the European Society of Cardiology Congress on September 1, 2013 and published in the New England Journal of Medicine.8,9

About Daiichi Sankyo 

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu 
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

<
'/>"/>
SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... -- "Whether it,s our family, our friends, all of ... a single sentence, Dr. Anthony Coyle , senior ... Centers for Therapeutic Innovation (CTI), sums up what ... biopharmaceutical companies. CTI,s unique model allows ... and the National Institutes of Health (NIH) to bridge ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... SILVER SPRING, Md., Dec. 20, 2010 Each year, ... drugs that treat a wide variety of conditions and ... recent significant FDA approvals for generic medications, go to ... notices of new FDA Consumer Updates at: ...
... Inc. today announced the development of software that uses ... assist ophthalmologists and optometrists in diagnosing retinal and optic ... is an imaging technique used to provide ophthalmologists and ... (RNFL) which can help them diagnose diseases like glaucoma. ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2
(Date:3/27/2015)... TX (PRWEB) March 27, 2015 The ... is an essential source of information on and analysis ... US. The population of the US in 2013 amounted ... Growth Rate (CAGR) of 0.8% from 2008. The country’s ... of chronic diseases will help to boost the growth ...
(Date:3/27/2015)... Naples, FL and London, UK (PRWEB) March 27, 2015 ... solution, announced today that it has appointed Sean Fitzgerald, ... the role of Chief Operating Officer and Interim Chief ... Vice President of leading education technology innovator, EverFi, backed ... Eric Schmidt, and Twitter founder Evan Williams. Prior to ...
(Date:3/27/2015)... GrassrootsHealth, an international nonprofit public health ... NOW! vitamin D demonstration project April 7 in the ... (MUSC), and will soon follow with a second phase ... to a minimum of 500 pregnant women at 17 ... service areas. The project will include patient and health ...
(Date:3/27/2015)... 2015 When struck with the aftermath ... know where to begin. The latest eBook released ... attorney, offers accident victims a clear and concise process ... ensure their personal injury claim is seen through to ... first actions that should be taken immediately following the ...
(Date:3/27/2015)... Trail mix is the perfect, healthy snack ... hikes and during the game! It’s portable, lightweight and provides ... to introduce a new line of specialty trail mixes that ... flavorful selections packed with nutritious, 100% all natural ingredients. , ... that add protein and fiber to your diet and boost ...
Breaking Medicine News(10 mins):Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2
... Older adults who don,t get enough vitamin D ... at increased risk of developing mobility limitations and disability, according ... "This is one of the first studies to look at ... mobility limitations or disability in older adults," said lead author ...
... been approved since March 2011 in men with metastatic ... with hormone blockers and have already been pre-treated with ... pursuant to the "Act on the Reform of the ... Quality and Efficiency in Health Care (IQWiG) examined whether ...
... of Physicians (ACP), the second-largest physician group in the United ... aims to prevent one million heart attacks and strokes in ... Empowering Americans to make healthy choices such as preventing ... can reduce the number of people who need medical treatment ...
... Vitamin D deficiency is not healthy. However, new research from ... level of the essential vitamin is not good either. The ... results have just been published in the reputed scientific ... is instrumental in helping calcium reach our bones, thus lessening ...
... aspirin and other similar painkillers may help protect against ... a peer-reviewed journal of the American Cancer Society, the ... to the benefits of these commonly used medications. ... NSAIDs, which include aspirin, ibuprofen, and naproxen, as well ...
... Aggressive efforts to lower blood pressure in people with ... a new study The research shows that there ... with diabetes in the U.S. Department of Veterans Affairs, with ... controlled and 94 percent getting appropriate BP treatment. ...
Cached Medicine News:Health News:Older adults may need more vitamin D to prevent mobility difficulties 2Health News:Cabazitaxel can offer an advantage in certain patients 2Health News:Cabazitaxel can offer an advantage in certain patients 3Health News:ACP joins Million Hearts to help save lives from preventable heart attacks and strokes 2Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Commonly used painkillers may protect against skin cancer 2Health News:1 size doesn't fit all when treating blood pressure in people with diabetes, VA/U-M study suggests 2Health News:1 size doesn't fit all when treating blood pressure in people with diabetes, VA/U-M study suggests 3
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... SEDIPLAST® is a completely closed system ... laboratory personnel from the risk associated ... uniquely designed erythrocyte sedimentation rate test ... convenience as well as reliable and ...
... Unlike other ESR products, SEDIPLAST® is ... design features to protect laboratory personnel ... handling. SEDIPLAST® is a uniquely designed ... provides greater safety and convenience as ...
... The use of guaiac as ... of blood is based on ... present in guaiac to quinones, ... a blue color. If blood ...
Medicine Products: